icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a
 
 
  Reported by Jules Levin
EASL 2018 April 11-15 Paris France

0521181

0521182

0521183

0521184

0521185

0521186

0521187

0521188

0521189

05211810

05211811